Using blood as a non-invasive clinical tool, these studies found that SFRP2 methylation was predominantly hypermethylated in blood samples [27], including circulating tumor cells (CTCs) [28], in serum [29], circulating free DNA [30, 31], and plasma [32, 33]. This evidence concerns the gene SFRP2 and neoplasm.